Masimo introduces the new Rad-87 Pulse CO-Oximeter, Patient SafetyNet, and
noninvasive hemoglobin
IRVINE, Calif., May 6 /PRNewswire-FirstCall/ -- Masimo, the inventor of
Pulse CO-Oximetry and Measure-Through-Motion-and-Low-Perfusion Pulse Oximetry,
will showcase the latest technology for patient safety solutions at the
American Association of Critical Care Nurses (AACN), National Teaching
Institute (NTI) & Critical Care Exposition in Chicago on May 6-8, 2008. Live
demonstrations of the new Masimo Rad-87 Pulse CO-Oximeter(TM), Masimo Patient
SafetyNet(TM) and continuous, noninvasive hemoglobin (SpHb(TM)) (pending FDA
clearance) will show how Masimo technologies can help critical care clinicians
advance patient safety, improve patient outcomes, and increase clinical
efficiencies.
This year, the Joint Commission, an independent, not-for-profit
organization that accredits and certifies more than 15,000 health care
organizations and programs in the United States, recognized improved
recognition and response to changes in a patient's condition as one of their
key National Patient Safety Goals.
A key foundational component to improving patient safety on the general
floor is the unprecedented sensitivity and specificity of Masimo SET pulse
oximetry. Before Masimo SET, pulse oximeters were reported to falsely alarm
more than 90% of the time. In fact, one major hospital attempted to monitor
patients on the general floor before the advent of Masimo SET and reported
thousands of false alarms per month.
Another key component to improving clinician response to changing patient
conditions on the general care floor is Masimo Patient SafetyNet-a new
easy-to-use remote monitoring and clinician notification system that reliably
and cost-effectively delivers patient alarms to assigned clinicians.
Combining the "gold standard" performance of Masimo SET(R) pulse oximetry with
wireless clinician notification via pager, Patient SafetyNet provides a new
level of safety to patients on general care floors.
A perfect complement to Masimo SET and Patient SafetyNet is the new Masimo
Rad-87 bedside monitor. The Rad-87 is an easy-to-use, yet fully-featured
Pulse CO-Oximeter with a built-in 802-11a/b/g radio for bidirectional wireless
communication with the Patient SafetyNet system. Recently cleared by the FDA,
it features a simple, intuitive user-interface design with an easy-to-read,
high-contrast display that allows clinicians to clearly see the Masimo Rainbow
SET measurements-even from across the room. Alarms and alerts can be enabled
at the bedside or remotely, via the Patient SafetyNet system. Rad-87 allows
activation of many features with only a single touch and its unique visual
display allows users to quickly confirm if the alarm settings are appropriate
for the patient environment.
Rad-87 also features Masimo Rainbow SET, the first-and-only noninvasive
blood constituent monitoring platform measuring carboxyhemoglobin (SpCO(R)),
methemoglobin (SpMet(R)), and PVITM, in addition to oxyhemoglobin (SpO2),
perfusion index (PI), and pulse rate. A cost-effective solution for critical
care customers who value ease-of-use and versatility, Rad-87 will also be
capable of displaying Masimo's newest Rainbow measurement-noninvasive total
hemoglobin (SpHb(TM)) (pending FDA clearance).
As the Anesthesiology Patient Safety Foundation (APSF) has recommended,
continuous monitoring of oxygenation (pulse oximetry) and ventilation should
reduce the incidence of preventable postoperative death and injury on the
general care floors.(1) Rad-87 and Patient SafetyNet should help hospitals
provide the level of care their patients on the general floors need without
the burden of excessive false alarms on their already stretched resources.
In addition, Rad-87's ability to provide noninvasive and continuous
hemoglobin monitoring should help improve patient outcomes and reduce the cost
of care by providing real-time anemia monitoring-potentially allowing
clinicians to perform fewer lab tests, better manage blood transfusions, speed
detection of internal bleeding, and more efficiently assess chronic anemia.
Joe E. Kiani, CEO of Masimo, stated, "Masimo has had a longstanding
commitment to 'do what is best for patient care' through innovation. The new
Rad-87, Patient SafetyNet and Rainbow SET technologies that we are presenting
to the critical care community at the AACN underscore our commitment and
highlight our continued focus on developing innovative monitoring solutions to
empower healthcare professionals to provide more advanced and comprehensive
care to their patients."
Sponsored by the American Association of Critical Care Nurses, the NTI &
Critical Care Exposition is the largest and most comprehensive trade show for
acute and critical care nurses.
About Masimo
Masimo (Nasdaq: MASI) develops innovative monitoring technologies that
significantly improve patient care -- helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulse
oximetry, known as Masimo SET, which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides the
most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion. In
2005, Masimo introduced Masimo Rainbow SET, a breakthrough noninvasive blood
constituent monitoring platform that can measure many blood constituents that
previously required invasive procedures. Rainbow SET continuously and
noninvasively measures total hemoglobin (SpHb(TM)) and oxygen content
(SpOC(TM)) (both pending regulatory clearances), carboxyhemoglobin (SpCO(R)),
methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2),
pulse rate (PR), and perfusion index (PI), allowing early detection and
treatment of potentially life-threatening conditions. Founded in 1989, Masimo
has the mission of "Improving Patient Outcomes and Reducing Cost of Care by
Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at
http://www.masimo.com.
Forward Looking Statements
This press release may include forward-looking statements. These
forward-looking statements are based on current expectations about future
events affecting us and are subject to uncertainties and factors, all of which
are difficult to predict and many of which are beyond our control, including:
risks related to our assumption that Masimo Patient SafetyNet, Rad-87, Masimo
SET and Masimo Rainbow SET technologies will deliver a sufficient level of
clinical improvement to allow for further adoption of pulse oximetry or Pulse
CO-Oximetry on the general care floors and risks related to our assumption
that Masimo's new noninvasive measurements -- total hemoglobin (SpHb(TM)) and
oxygen content (SpOC(TM)) -- will deliver a sufficient level of clinical
improvement over alternative invasive testing capabilities to allow for rapid
adoption of the technology and risks related to our assumptions regarding the
timing or commercial availability of SpHb and SpOC, and will be timely cleared,
if ever, by appropriate regulatory bodies, as well as other factors discussed
in the "Risk Factors" section of our quarterly report on Form 10-Q for the
quarter ended March 29, 2008, filed with the Securities and Exchange
Commission on May 1, 2008. Although we believe that the expectations reflected
in our forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date hereof.
We do not undertake any obligation to update, amend or clarify these
forward-looking statements or the risk factors contained in our quarterly
report on Form 10-Q for the quarter ended March 29, 2008, whether as a result
of new information, future events or otherwise, except as may be required
under the federal securities laws.
(1) Anesthesia Patient Safety Foundation (ASPF) Initiatives: "Safety
During Patient-Controlled Analgesia"; October 13, 2006.
http://www.apsf.org/initiatives/pca.mspx
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and
Applications, Rainbow, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57, Rad-9,
Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or
registered trademarks of Masimo Corporation.
SOURCE Masimo
CONTACT: Dana Banks of Masimo Corporation, +1-949-297-7348
Web site: http://www.masimo.com